CTOs on the Move

Boston MicroFluidics

www.bostonmicrofluidics.com

 
Boston Microfluidics (BMF) is dedicated to connecting people to their health by increasing access to diagnostic testing for all people. Our technology is a unique combination of elegant sample processing solutions with an intuitive user interface. We strive to streamline current testing systems with devices that perform complex sample processing steps without the need for trained professionals or specialized laboratory equipment. We also seek to simplify diagnostic tests so that they can be used efficiently at the point of care, or even be available for direct sale to consumers. Above all, BMF works to help provide patients with ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

Boston MicroFluidics raised $17.5M on 08/27/2019

Similar Companies

Siloam Family Health Center

Siloam Family Health Center is a Nashville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

medicadepot.com

medicadepot.com is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Good Chemistry

Good Chemistry Nurseries is a leading producer of Cannabis products and related services, and is committed to leading the way for people through the growth, production and use of cannabis. Good Chemistry Nurseries is dedicated to cultivating the most c...

Back Nursery

Back Nursery is a Hastings, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Portola

Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.